Miscellaneous News

RSS

Curia to expand U.S. commercial manufacturing capability

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced plans to expand its commercial manufacturing capacity at its Rensselaer, New York facility.

From Curia 23 Aug 2021

Parts of Lake Tahoe close after chipmunks test positive for plague

Officials are closing some areas on the south shore of Lake Tahoe after some chipmunks tested positive for plague, an infectious disease that affects both humans and other mammals.

4 Aug 2021

How women in England faced childbirth in the COVID-19 pandemic

Pregnant women have suffered considerable uncertainty during the COVID-19 pandemic. Not only were the effects of the virus on the baby unknown, but social restrictions in place threatened their ability to plan their delivery experience or have their birthing partners with them. This is the focus of a new paper, which illustrates the need to provide proper guidance and support to pregnant women during such periods, especially allowing them to feel supported and in control of their childbirth experience.

8 Jul 2021

Study explores contemporary attitudes towards wealth transfer taxation in Australia

Cash in on the kids' inheritance and spend up big on the retirement plans - that's the message coming from the University of South Australia as new research reveals that older people are keen to spend their well-earned savings, rather than passing them on to their kids.

2 Jul 2021

UK study finds SARS-CoV-2 antibodies in domestic cats and dogs

Researchers analyzed sera from pet cats and dogs and found them to have developed antibodies against the virus later on during the COVID-19 pandemic. These findings suggest that viral prevalence among the human populations could have led to the pets becoming infected.

28 Jun 2021

Nanotechnology and artificial intelligence may be valuable components in securing global food production

An international team of researchers led by scientists at the University of Birmingham, UK, developed a series of steps to follow that could harness AI and integrate the power of nanomaterials safely, sustainably and responsibly, into agricultural practices..

24 Jun 2021

Combination of interferon-α and nafamostat inhibits SARS-CoV-2 in vivo

A new study, released as a preprint on bioRxiv* server, shows that a combination of the biological interferon-α and the small molecule nafamostat are effective against SARS-CoV-2 infection in vitro, as well as in vivo.

18 Jun 2021

What impacts public compliance with COVID-19 restrictions?

New research by scientists at Switzerland's Institute for Environmental Decisions reports that risk perception and public acceptance of NPIs depends on both worldview and levels of social trust. The study also found that, paradoxically, when the number of cases decreased in the period between the first and second waves, public willingness to comply with these measures fell.

17 Jun 2021

Does SARS-CoV-2 show seasonal variation in transmission in temperate countries?

The need to understand how and why such spread occurs is vital to containing it. A new medRxiv* preprint describes a significant reduction in transmission during the summer (by 42%), which is comparable to the impact of the most effective non-pharmaceutical intervention (NPI).

15 Jun 2021

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

A new study, released on the bioRxiv* preprint server, supports the efficacy of the wildtype ChAdOx1 nCoV-19 (AZD1222) vaccine against B.1.351, B.1.617.1 and B.1.617.2, while showing that a booster dose of vaccine based on the B.1.351 spike induces further increase in antibody titers.

11 Jun 2021

Scientists detect delayed and reduced antibody responses after BioNTech/Pfizer COVID-19 vaccination in older adults

Researchers at the U.S. Centers for Disease Control and Prevention (CDC) detected delayed and reduced antibody and T cell responses after immunization with BNT162b2 or the Pfizer-BioNTech COVID-19 vaccine in older adults compared with healthcare workers in Germany.

11 Jun 2021

Bovine-derived polyclonal antibodies exhibit high efficacy in neutralizing SARS-CoV-2 variants

A team of scientists in Estonia has recently evaluated the therapeutic/prophylactic efficacy of anti-SARS-CoV-2 polyclonal antibodies derived from the colostrum of immunized cows.

10 Jun 2021

A closer look at how COVID-19 damages human lungs

A recent study conducted at the United States Department of Energy’s (DOE) Brookhaven National Laboratory provides the first atomic-level detailed model of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) envelope protein when bound to human proteins within the lungs. The study was recently published in Nature Communications.

9 Jun 2021

Could the intranasal route be an alternate avenue of COVID-19 vaccination?

A new study has been published in the journal Vaccines that summarizes the history of vaccines, reviews the current progress in COVID-19 vaccine technology, and discusses the status of intranasal COVID-19 vaccines as a potential pathway to immunization.

8 Jun 2021

Iksuda Therapeutics closes $47 million financing round

Iksuda Therapeutics (Iksuda) has announced it has completed a US $47 million (circa GB £34 million) financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. The funding will support the advancement of Iksuda’s lead ADC assets and expansion of its payload and conjugation platform technologies.

From Iksuda Therapeutics 8 Jun 2021

Compelling evidence of SARS-CoV-2 exposure and neutralizing antibodies in domestic cats in Peru

Although Peru is one of the countries most affected by the pandemic, no studies had been conducted to investigate SARS-CoV-2 seroprevalence among domestic cats. Recently, researchers from Peru demonstrated the presence of neutralizing antibodies for the receptor binding-domain (RBD) of the SARS-CoV-2 spike protein in cats in Lima, Peru. The owners of the cats in the study had confirmed SARS-CoV-2 infection.

1 Jun 2021

Antibody cocktail effectively inhibits SARS-CoV-2 in the rhesus macaque model

Researchers from the US tested the prophylactic potential of a combination of 2 mAbs administered 3 or 75 days before respiratory challenge in rhesus macaques. They used the rhesus macaque model to test the added benefit of combinatory parenteral administration of 2 high-affinity anti-SARS-CoV-2 mAbs - C144-LS and C135-LS. These mAbs were developed to neutralize the virus and tweaked to improve their pharmacokinetics.

1 Jun 2021

ALG-097111 potently inhibits SARS-CoV-2 replication in Syrian Hamster model in vivo

A team of researchers from the US and Belgium applied a structure-based approach with early monitoring of cathepsin L inhibition along with SARS-CoV-2 3CLpro inhibition. They identified a potent and selective SARS-CoV-2 3CLpro inhibitor, ALG-097111, which has proven activity against SARS-CoV-2 in SARS-CoV-2 hamster models in vivo. This study is published in the journal, Biochemical and Biophysical Research Communications.

1 Jun 2021

Study offers longitudinal roadmap of immune activation and resolution in mild COVID-19

Researchers from the US recently profiled the longitudinal immune response in mild COVID-19 patients starting with early time points of 1-15 days post-infection through convalescence to over 100 days after onset of symptoms.

1 Jun 2021

Researchers repurpose pre-existing anti-SARS-CoV antibody to develop potent neutralizing antibody against SARS-CoV-2

A team of scientists from the United States has recently engineered a pre-existing anti-severe acute respiratory syndrome coronavirus (SARS-CoV) neutralizing antibody to increase its binding affinity for the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The engineered antibody demonstrates high potency in neutralizing SARS-CoV-2 and preventing infection in animals.

31 May 2021

Miscellaneous News

Curia to expand U.S. commercial manufacturing capability

Parts of Lake Tahoe close after chipmunks test positive for plague

How women in England faced childbirth in the COVID-19 pandemic

Study explores contemporary attitudes towards wealth transfer taxation in Australia

UK study finds SARS-CoV-2 antibodies in domestic cats and dogs

Nanotechnology and artificial intelligence may be valuable components in securing global food production

Combination of interferon-α and nafamostat inhibits SARS-CoV-2 in vivo

What impacts public compliance with COVID-19 restrictions?

Does SARS-CoV-2 show seasonal variation in transmission in temperate countries?

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

Scientists detect delayed and reduced antibody responses after BioNTech/Pfizer COVID-19 vaccination in older adults

Bovine-derived polyclonal antibodies exhibit high efficacy in neutralizing SARS-CoV-2 variants

A closer look at how COVID-19 damages human lungs

Could the intranasal route be an alternate avenue of COVID-19 vaccination?

Iksuda Therapeutics closes $47 million financing round

Compelling evidence of SARS-CoV-2 exposure and neutralizing antibodies in domestic cats in Peru

Antibody cocktail effectively inhibits SARS-CoV-2 in the rhesus macaque model

ALG-097111 potently inhibits SARS-CoV-2 replication in Syrian Hamster model in vivo

Study offers longitudinal roadmap of immune activation and resolution in mild COVID-19

Researchers repurpose pre-existing anti-SARS-CoV antibody to develop potent neutralizing antibody against SARS-CoV-2

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News